SSY GROUP (02005) has obtained the drug production registration certificate for 0.4ml ketotifen fumarate eye drops (0.025%) in single-dose packaging from the National Medical Products Administration.

SSY GROUP (02005) announces that the group has obtained the drug production registration approval from the National Medical Products Administration of China (NMPA) for the 0.4ml Ketotifen Fumarate Ophthalmic Solution (0.025%) (this product) in single-dose packaging. It belongs to the third category of chemical drugs and is considered equivalent through consistency evaluation. This product is mainly used for symptomatic treatment of seasonal allergic conjunctivitis. This product is the second domestically produced approved by the NMPA and the third eye formulation product of the group. The board of directors is pleased to announce that the group has also obtained the drug production registration approval from the NMPA for the Calcium Gluconate Injection (10ml:1g), which belongs to the third category of chemical drugs and is considered equivalent through consistency evaluation. Calcium Gluconate Injection is mainly used for the treatment of acute hypocalcemia, magnesium and fluoride poisoning.